[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Chaikovsky, 2021 - Google Patents

Using CDK4/6 Inhibitors to Identify Novel Regulators of the RB Pathway

Chaikovsky, 2021

Document ID
4958369236617932982
Author
Chaikovsky A
Publication year

External Links

Snippet

The initiation of cell division is a fundamental cellular process that integrates a large number of intra-and extra-cellular inputs. In mammalian cells, D-type cyclins (cyclin D1, D2, and D3, together" cyclin D") couple these inputs to the decision to initiate DNA replication. Increased …
Continue reading at search.proquest.com (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid

Similar Documents

Publication Publication Date Title
Jiang et al. Direct phosphorylation and stabilization of MYC by aurora B kinase promote T-cell leukemogenesis
Xiong et al. USP8 inhibition reshapes an inflamed tumor microenvironment that potentiates the immunotherapy
Gupta et al. DNA repair network analysis reveals shieldin as a key regulator of NHEJ and PARP inhibitor sensitivity
Thanasoula et al. ATM/ATR checkpoint activation downregulates CDC25C to prevent mitotic entry with uncapped telomeres
Diril et al. Loss of the Greatwall kinase weakens the spindle assembly checkpoint
Li et al. Integrated Genomic and Proteomic Analyses Reveal Novel Mechanisms of the Methyltransferase SETD2 in Renal Cell Carcinoma Development*[S]
Gatz et al. MCM3AP and POMP mutations cause a DNA‐repair and DNA‐damage‐signaling defect in an immunodeficient child
Schumann et al. Deficiency for SAMHD1 activates MDA5 in a cGAS/STING-dependent manner
Han et al. New role of human ribosomal protein S3: Regulation of cell cycle via phosphorylation by cyclin-dependent kinase 2
Shin et al. Targeting FLT3-TAZ signaling to suppress drug resistance in blast phase chronic myeloid leukemia
O'Connor et al. Protein phosphatase 2A Aα regulates Aβ protein expression and stability
US20240245664A1 (en) Methods of using usp15 inhibitors
Chaikovsky Using CDK4/6 Inhibitors to Identify Novel Regulators of the RB Pathway
Zhao et al. RAPSYN-mediated neddylation of BCR-ABL alternatively determines the fate of Philadelphia chromosome-positive leukemia
Deng et al. TNF and IFNγ-induced cell death requires IRF1 and ELAVL1 to promote CASP8 expression
Wang et al. Ubiquitin-like protein 5 is a novel player in the UPR–PERK arm and ER stress–induced cell death
Perlee et al. SETD1A function in leukemia is mediated through interaction with mitotic regulators BuGZ/BUB3
Machour et al. Harnessing DNA replication stress to target RBM10 deficiency in lung adenocarcinoma
Sakthivel et al. Caspase-2 is essential for proliferation and self-renewal of nucleophosmin-mutated acute myeloid leukemia
Harris Ubiquitination of proteins involved in metabolism and immunomodulatory drug sensitivity in lymphocytes
Tang Molecular Mechanisms of BTK Dependency in Primary CNS Lymphoma
Gordon et al. Catalytic inhibition of KAT6/KAT7 enhances the efficacy and overcomes primary and acquired resistance to Menin inhibitors in MLL leukaemia
Indeglia PADI4 REGULATES THE P53 PATHWAY AND TUMOR SUPPRESSION THROUGH CITRULLINATION AND IMMUNE ACTIVATION
García et al. Exploiting a PAX3-FOXO1-induced synthetic lethal ATR dependency for rhabdomyosarcoma therapy
Bertlin et al. VHL synthetic lethality screens uncover CBF-β as a negative regulator of STING